The treatment of organ rejection with immunosuppressive medication a discussion - Free Essay Example

Sample details Pages: 8 Words: 2438 Downloads: 5 Date added: 2017/06/26 Category Medicine Essay Type Essay any type Did you like this example? Since the pioneering experiments of allograft heart transplantation by Christiaan Barnard in 1967, there have been significant advances in the development of human organ transplantation. Indeed, over 35,000 patients in both the US and Europe benefit annually from organ transplantation (Hampton, 2005). Through the transplantation and engraftment of these organs, not only can biological function of organs be restored, but also the quality of life of recipients can be greatly increased. Don’t waste time! Our writers will create an original "The treatment of organ rejection with immunosuppressive medication: a discussion" essay for you Create order As a result the number of transplantation operations carried out each year has increase exponentially over the past decades. Despite improvements in surgical techniques, the hurdle of immunological rejection by the host of transplanted organs still remains a current obstacle. This represents a challenge both scientifically and clinically and, as a result, is a focus of both the medical and scientific communities. Over the past 60 years, there has been an exponential increase in the development of immunosuppressive drugs in order to treat organ rejection, as well as autoimmune diseases (Gummert et al. 1999). These drugs seek to suppress various components of the immune system in order to prevent rejection in the context of organ transplantation. This essay seeks to examine the broad immunology of transplantation as well as the different classes of immunosuppressive drugs and their associated benefits and side effects. Transplantation is broadly defined as the act of transferring cells, tissues, or organs from one site to another. In the context of organ transplantation, this is generally from one person to another, with transplantation classed as either from a living donor or cadaveric. Although less common, there has been some attempt to transplant organs from other animals, known as xenografts. This was initially attempted given the lack of availability of human donor organs. However, as transplantation occurs between two immunologically distinct persons, a degree of immunological mismatch occurs. Due to this mismatch, the host immune system recognises the donor organ as foreign and, as a result, activates various arms of the immune system. Several types of immune rejection can occur in individuals undergoing organ transplantation. Hyperacute rejection occurs when pre-existing antibodies within the host against donor antigens attack the graft and result in rapid rejection of the graft, typically within a few hours (Murphy et al. 2010). This results in rapid declining function of the graft and is often non-reversible, thereby causing the recipient to lose the graft. In contrast, acute rejection occurs within six months following transplantation and is the result of activated T cells against donor antigens (Murphy et al. 2010). The third type of rejection is known as chronic rejection and, as the name suggests, occurs years after transplantation and is mediated by both antibodies and T cells. In order to encourage graft survival, and prevent the aforementioned from occurring, effective regimes in order to suppress these immune responses have been developed, although as outlined, they often come with significant side effects. Glucocorticoids, such as prednisone, are commonly used in immunosuppressive regimes. These drugs seek to prevent rejection by suppressing various arms of the immune system including T cells, B cells, macrophages, granulocytes and monocytes (Steiner and Awdishu, 2011). These drugs are, therefore considered t o be relatively non-specific and highly potent leading to a range of side effects. Glucocorticoids exert their effects by regulating the activity and expression of various cytokines through inhibition of intracellular signalling pathways such as NF-kB. Through modulation of this complex signalling pathway, the production of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-alpha are greatly reduced (Schacke et al. 2002). Although these drugs feature heavily in clinical practice, they are associated with a significant number of side effects. Prolonged glucocorticoid use can lead to Cushings syndrome: a constellation of symptoms characterised by increased central adiposity, buffalo hump, osteoporosis and a round face (Schacke et al. 2002). These symptoms are due to excess exogenous cortisol within the body and therefore have multiple endocrinological effects on various physiological processes. The concentration of such drugs are therefore closely monitored and patients are encoura ged to monitor for symptoms suggestive of Cushings syndrome. As well as glucocorticoids, drugs known as antimetabolites are frequently used in immunosuppressive regimes. These drugs, such as azathioprine and mercaptopurine, amongst others, were originally developed in the 1950s, but remain used to this day. Azathioprine is commonly used for liver and kidney transplantation (Germani et al. 2009), as well as for the treatment of autoimmune conditions such as rheumatoid arthritis (Whisnant and Pelkey, 1982). Antimetabolites exert their immunosuppressive effects by blocking the synthesis of purine within cells (Murphy et al. 2010). Through the blockage of purine synthesis, DNA replication is unable to take place, thereby preventing expansion of rapidly dividing cells within the immune system. Through the blockade of T and B cell expansion, the level of rejection against organ transplants can be controlled. One considerable side effect associated with the use of azathioprine is the increased risk of skin cancer. A relatively recent review by Ulrich and Stockfleth (2006) has shown that sunlight exposure, pre and post transplantation in patients using azathioprine, correlates with an increased incidence of skin cancer. As exposure to UVA light damages skin cells: these cells are unable to undergo repair following damage, due to inhibition of DNA replication from azathioprine. In the long term, this accumulation of damage results in the increased propensity for patients to develop skin cancer. Current clinical guidelines suggest that clinicians discourage patients in spending prolonged periods of time in the sun following transplantation (Perrett et al. 2008). Along with these classes, of drugs, another category of immunosuppressive medications, known as calcineurin inhibitors, also work efficaciously in organ transplantation. These drugs, which include tacrolimus and cyclosporine, act by inhibiting the protein calcineurin. Calcineurin in activated following the presentation of an antigen by an antigen presenting cell, such as a dendritic cell or macrophage, to a T cell, resulting from an increase in the concentration of intracellular calcium (Reynolds and Al-Daraji, 2002). Following the activation of calcineurin, there is an increase in the production of interleukin 2 (IL-2), which causes the activation of T cells. As a result, this further propagates an immune response. Calcineurin inhibitors are, therefore, useful in dampening an immune response, preventing the activation of T cells against a transplanted organ. Calcineurin inhibitors are popular drugs used in renal transplantation. However, evidence over the past decade has suggested that drugs such as tacrolimus may induce renal failure in some patients (Ponticelli, 2000). Obviously this a key consideration when considering patients who already have poor renal function to being with. As a result, these drugs are often combined with other immunosuppressive agents and tailored to the lowest dosage possible. The understanding into the way in which the immune system functions has been exploited over the past thirty years with the development of monoclonal antibodies. Monoclonal antibodies were first developed in the 1970s through the fusion of rapidly proliferative myeloma cells with B cells to produce hybridomas (Liu, 2014). Antibodies are protein molecules that have a specific antigen-binding region enabling them to have a high degree of specificity. Antibodies have, therefore, been exploited therapeutically in order to target pathogenic molecules within the body. Recently, monoclonal antibodies have been developed to target various components of the immune responses in order to modulate organ rejection seen in patients. In particular, monoclonal antibodies have been developed to target T and B cells. Some examples of these therapeutics are discussed below. Muromonab is a monoclonal antibody, which is specific for cluster of differentiation 3 (CD3), a molecule found primarily on T cells (Murphy et al. 2010). By targeting T cells and preventing their activation against the transplanted organ, there is considerable evidence to show that this can significantly prolong the survival of the organ following transplantation, compared to glucocorticoid steroids (Authors not listed, 1985). However, despite the success of anti-CD3 therapy, there are substantial side effects associated with clinical use. Use of anti-CD3 has been associated with severe fever in patients, as well as the unwanted release of pro-inflammatory cytokines (Norman et al. 2000). As a result the use of anti-CD3 has declined in clinical practice and is reserved for treatment resistant cases of organ rejection. As well as muromonab, another mainstay treatment for organ rejection are antibodies directed against cluster of differentiation number 25 (CD25). Organ rejection is heavily mediated by T cells, in combination with other arms of the immune system (Ingulli, 2010) . When activated, T cells produce large amounts of IL-2, a cytokine that acts in an autocrine fashion to further expand T cells via the IL-2 receptor CD25. Therefore, blockade of CD25 with a monoclonal antibody was hypothesised to offer a novel target in treating immunological rejection by T cells. As a result, daclizumab was developed and was shown by Vincenti et al. in 1998 to be a successful tool in treating renal transplantation compared to using a combination therapy of cyclosporine, azathioprine and corticosteroids. Furthermore, more long term studies have examined the function of renal transplants and concluded that patients on daclizumab showed improved renal function, as established by estimated glomerular filtration rate (GFR) (Ferran et al. 1990). However, like other pharmacological treatments, daclizumab has also been shown to cause a significant number of side effects such as hypertension and insomnia (EPAR for Zenapax). More recently, the scientific community has so ught to develop more refined immunological tools in order to modulate rejection. Through the development of monoclonal antibodies targeting cluster of differentiation 52 (CD52), clinicians are able to target lymphocytes for destruction, sparing the destruction of resident haematopoetic stem cell populations (Flynn and Byrd, 2000). Anti-CD52 drugs were originally developed for multiple sclerosis (Coles et al. 2008) and trials are currently being undertaken to establish their efficacy in organ transplantation. The overarching side effect with immunosuppressive regimes is the relatively blanket level of immunosuppression which they cause. Although immunosuppression is required to maintain organ survival, immunosuppression also results in a reduced ability to fight infections. In particular, pulmonary infections are common in organ transplant patients, with Hoyo et al. (2012) detailing that around 1 in 5 patients in their study developed pulmonary infections. It is clear that clinici ans dealing with organ transplantation patients must remain vigilant for infections. It is similarly clear, therefore, that a fine balance of the level of immunosuppression should be reached: a heavily weighted level will pre-dispose to opportunistic infections, and, conversely, a lightly weighted level will result in organ rejection. With respect to future outlooks in transplantation immunology, the development of pluripotent stem cells has been hypothesised to overcome immunological issues associated with organ transplantation. Through the use of induced pluripotent stem cells (iPS cells) developed by Takahashi et al. (2006) it has been shown that it is possible to differentiate nearly all existing cell types. As these cells are derived from the patient, they are immunologically matched to the individual and, as a result, patients would not require harsh immunosuppressive regimes. Although this technology has not been tested clinically in patients extensively yet, it is hoped t hat within the next twenty years this method will provide an unlimited source of organ replacement for patients. Use of such cells is currently being explored for regeneration of certain organs such as the heart (Masumoto, 2014). Use of these cells will require a significant amount of clinical testing to determine their immunological properties, as well as their propensity to develop into tumours. It is likely, therefore, that the clinical applications of stem cells are still many years away. In conclusion, despite significant improvements in targeted immunosuppressive regimes, significant side effects are associated with current pharmacological treatments. Clearly, as patients treated with these agents are often susceptible to opportunistic infections, their progress must be monitored closely by a clinician who is familiar with such patients, and the complications they can present with. Through our increased understanding of the immune system, alongside new technologies such as stem cell replacement therapy, it is hoped that the immunological issues associated with organ transplantation will in the near future be overcome. Bibliography Authors not listed (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med. 313:337à ¢Ã¢â€š ¬Ã¢â‚¬Å"342 Coles, A., Lake, S. and Moran, S. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. NEJM. 359: 1786-1801. EPAR for Zenapax. European Medicines Agency. 2007. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000198/WC500057570.pdf Gummert, J., Ikonen, T. and Morris, R. (1999) Newer immunosuppressive drugs: a review. J Am Soc Nephrol. 10(6):1366-80. Hoyo, I. Sanclemenete, G., Cervera, C. (2012) Opportunistic pulmonary infections in solid organ transplant recipients. Transplant Proc. ;44(9):2673-5 Ferran, C., Dy, M., Merite, S., Sheehan, K., Schreiber, R., Leboulenger, F. (1990) Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation. 50:642à ƒ ¢Ã¢â€š ¬Ã¢â‚¬Å"648. Flynn, J. and Byrd, J. (2000) Campath1H monoclonal antibody therapy. Current. Opinion in Oncology. 12(6) 574-581. Germani, G., Tschochatiz, E., Adreana, L. and Burroughs, A. (2009) Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant. 9(8):1725-3 Hampton, T. (2005) Skin cancers ranks rise: immunosuppression to blame. JAMA. 294: 1476-1480. Ingulli, E. (2010) Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 25(1): 61à ¢Ã¢â€š ¬Ã¢â‚¬Å"74. Liu, J. (2014) The history of monoclonal antibody development à ¢Ã¢â€š ¬Ã¢â‚¬Å" Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 3(4): 113à ¢Ã¢â€š ¬Ã¢â‚¬Å"116. Masumoto, H., Ikeda, T., Okano, T., Sakata, R. and Yamashita, J. (2014) Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Scientific Reports. 4: 6716/ Murphy KM, P Trave rs, M Walport (Eds.) (2010) Janeways Immunobiology. 8th Edition. New York:Taylor Francis, Inc. Norman, D. J., Vincenti, F., de Mattos, A.M., Barry, J.M., Levitt, D.J., Wedel, N.I. (2000) Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation. 70:1707à ¢Ã¢â€š ¬Ã¢â‚¬Å"1712 Perrett, C., Walker, S., Warwick, J., Harwood, C., Karran, P. and McGregor, J. (2008) Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. BJD. 159(1): 198-204. Ponticelli, C. (2000) Calcineurinà ¢Ã¢â€š ¬?inhibitors in renal transplantation. Too precious to be abandoned. Nephrol. Dial. Transplant. 15 (9): 1307-1309. Reynolds, N. and Al-Daraji, W. (2002) Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol. 27(7):555-61. Schacke, H., Docke, W. and Asadullah, K. (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacology and Therapeutics. 96(1): 22-43. Steiner, R. and Awdishu, L. (2011) Steroids in kidney transplantation. Semin. Immunopathol. 33(2): 157-167. Takahashi, K. and Yamanaka, S. (2006) Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 126(4): 663-676. Ulrich, C. and Stockfleth, E. (2007) Azathioprine, UV light, and skin cancer in organ transplant patientsà ¢Ã¢â€š ¬Ã¢â‚¬ do we have an answer? Nephrol. Dial. Transplant. 22 (4): 1027-1029 Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 338:161à ¢Ã¢â€š ¬Ã¢â‚¬Å"165 Whisnant, J. and Pelkey, J. (1982) Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. Ann Rheum Dis. 41(Suppl 1): 44à ¢Ã¢â€š ¬Ã¢â‚¬Å"47.

Freshman Vs Lazy Seniors Time And Time Essay - 1351 Words

Bubbly Freshmen vs Lazy Seniors Time and time again we see movies, plays, books, graphic novels, and many more mediums portraying the ‘average’ life of a high schooler. Sometimes these media adaptions hit the nail on the head but most of them turn out to be just another cliche in the genre. Most people often focus on high school and its inhabitants as a single organism when in reality it’s a complex hierarchy of ever-evolving individuals. To an outsider high school is no more complex than a simple arithmetic problem like one plus one. But from an insider s point of view one plus one suddenly expands to include several polynomials, introducing new variables that add layers to the rapidly expanding equation. One of the lesser explored areas of high school is its social order. At the base of the pyramid we have the Freshmen, fondly called the ‘babies’ of the school, that are always eager to please. Then there are the Sophomores who still retain their fi rst-year enthusiasm with an underlying layer of experience. Nearing the top are the Juniors that have already established the foundation of their personal identity and carry a wide array of knowledge. Then, sitting on the throne, are the Seniors who have an uncanny habit of bending the rules and have the nonchalance personality of a cat that only high school veterans can achieve. It’s simple for adults and even children to say that freshmen and seniors are virtually the same thing. However, if one looks underneath theShow MoreRelatedCollege Decisions: On or Off Campus?1361 Words   |  5 PagesUpcoming college freshman face a multitude of different and challenging decisions during their senior year of high school including deciding whether to live on campus or off campus. Each choice presents its own positives and negatives. The choice does not come easy because every student will have his or her own opinion of what is important. Both living on campus or off campus have t heir advantages and disadvantages but on campus living can be more beneficial in the end. In order to makeRead MoreTeaching Methods : Banking And Problem Posing1580 Words   |  7 Pagesbut problem-posing education gives students the control to creativity and the world around them to see a problem and find a solution to it (Freire, 1993). Freire states that this approach overcomes the alienating of students and stops the oppressor vs oppressed idea (Freire, 1993). Freire (1993) makes a point to say that problem-posing education makes students critical thinkers and allows people to move ahead and look forward. To give the students the â€Å"humanism† idea, Freire (1993), states that theyRead MoreStephen P. Robbins Timothy A. Judge (2011) Organizational Behaviour 15th Edition New Jersey: Prentice Hall393164 Words   |  1573 PagesEditor: Brian Mickelson Editorial Project Manager: Sarah Holle Editorial Assistant: Ashlee Bradbury VP Director of Marketing: Patrice Lu mumba Jones Senior Marketing Manager: Nikki Ayana Jones Senior Managing Editor: Judy Leale Production Project Manager: Becca Groves Senior Operations Supervisor: Arnold Vila Operations Specialist: Cathleen Petersen Senior Art Director: Janet Slowik Art Director: Kenny Beck Text and Cover Designer: Wanda Espana OB Poll Graphics: Electra Graphics Cover Art: honey comb

How Job Order Costing is Sub-used for Product Costing Purposes

Question: How Job Order Costing is Sub-used for Product Costing Purposes? Answer: Introduction In a product costing system, the costs incurred in a production process are accumulated and assigned to the organizations final products whereas job-order costing system is used by organizations where goods are produced in batches and these batches have significant differences. Made to order products are manufactured in job order costing and here every product produced is considered as a job. It captures and tracks by job the producing cost for each job including materials, labor and other things involved in a manufacturing environment (Finkler, 1994). More accurate product costing is achieved by computing rates of two different batches instead of the entire plant rate. Advantages Introducing the job order costing system provides the companies with better cost control over the jobs (the specific products produced) that are in production, better inventory valuation for financial statement, better ability to make certain that materials procured for a particular job was used for that purpose, ability to obtain information about how to prevent product stock-outs or stoppage in production and create an appropriate timeline for completing a job (Hansen Mowen, 2003). Job Order Costing Process For instance, let us consider small computer manufacturing companies. Market researchers estimate that these companies control around 25% of the market share in spite of big brand names advertising and cost cutting. Because small PC manufacturers build customized computers ranging from cutting-edge technology machines to older cheaper components for buyers who are budget minded. These manufacturers use the job order costing method to trace the costs of the different systems they produce (Hansen Mowen, 2003). Journal entries illustrating the flow of costs including direct material costs, labor costs and overhead costs of the fabrication department working on several distinct batches during a month is made. The details for posting to the different jobs would be presented in the journal entry explanations. When an individual job is completed, the costs are transferred to the finished goods inventory and once delivered, to the costs of sold goods (Finkler, 1994). All department managers can use completed job order cost sheet to determine how well the costs were managed. The job cost information is used by managers to make decisions and plan and control operations. Manufacturing companies thus incorporate job order costing as a means for controlling materials usage, equipment used in production and the labor costs incurred. Whether an entity is a manufacturer or a service organization tailoring its output according to specific customer needs, company managements find job order costing techniques most helpful in performing managerial functions. It is most useful in determining the costs of goods produced or rendered services in organizations that can attach costs to specific jobs; as the variety of products produced in organization increases, the size of the production lots decrease making job order costing more applicable (Kinney Raiborn, 2009). Job order costing is used in both manufacturing and non-manufacturing units that produce unique or heterogeneous products as cost is accounted by the individual job using a subsidiary account known as the job order cost sheet. References Finkler, S. (1994).Essentials of cost accounting for health care organizations. Gaithersburg, Md.: Aspen Publishers. Hansen, D., Mowen, M. (2003).Cost management. Mason, Ohio: Thomson/South-Western. Kinney, M., Raiborn, C. (2009).Cost accounting. Mason, OH, USA: Thomson/South-Western.

Internet IT Essays - Computer-mediated Communication, Online Chat

Internet IT The internet offers a huge wealth of information both good and bad, unfortunately the vary nature of the internet makes policing this new domain practically impossible. The internet began as a small university network in the United States and has blossomed into a vast telecommunications network spanning the globe. Today the internet is ruled by no governing body and it is an open society for ideas to be developed and shared in. Unfortunately every society has its seedy underside and the internet is no exception. To fully understand the many layers to this problem, an understanding of net history is required. Some thirty years ago the RAND corporation, Americas first and foremost Cold War think-tank faced a strange strategic problem. The cold war had spawned technologies that allowed countries with nuclear capability to target multiple cities with one missile fired from the other side of the world. Post-nuclear America would need a command and control network, linked from city to city, state to state and base to base. No matter how thoroughly that network was armored or protected, its switches and wiring would always be vulnerable to the impact of atomic bombs. A nuclear bombardment would reduce any network to tatters. Any central authority would be an obvious and immediate target for enemy missiles. The center of a network would be the first place to go. So RAND mulled over this puzzle in deep military secrecy and arrived at their solution. In 1964 their proposed ideas became public. Their network would have no central authority, and it would be designed from the beginning to operate while in tatters. All the nodes in the network would be equal in status to all other nodes, each node having its own authority to originate, pass and receive messages. The messages themselves would be divided into packets, each packet separately addressed. Each packet would begin at some specified source node and end at some other specified destination node. The particular route that the packet took would be unimportant, only the final results counted. Each packet would be tossed around like a hot potato from node to node, more or less in the direction of its destination, until it ended up in the proper place. If big chunks of the network were blown away, which wouldn't matter, the packets would still stay airborne, moving across the field by whatever nodes happened to survive. This system was efficient in any means (especially when compared to the phone system), but it was extremely tough. In the 1960's this concept was thrown around by RAND, MIT and UCLA. In 1969 the first such node was installed in UCLA. By December of 69, there were four nodes on the network, which was called ARPANET, after its Pentagon sponsor. The nodes of the network were high-speed supercomputers. (supercomputers at the time, desktop machines now) Thanks to APRANET scientists and researchers could share one another's computer facilities over long-distances. By the second year of its operation however, APRANET's users had warped the high cost, computer sharing network into a dedicated, high-speed, federally subsidized electronic post office. The main bulk of traffic on ARPANET was not long-distance computing, it was news and personal messages. The incredibly expensive network using the fastest computers on the planet was a message base for gossip and schmooze. Throughout the 70s this very fact made the network grow, its software allowed many different types of computers to become part of the network. Since the network was decentralized it was difficult to stop people from barging in and linking up. In fact nobody wanted to stop them from joining up and this branching complex of networks came to be known as the internet. In 1984 the National Science Foundation got into the act, and the new NSFNET set a blistering pace for technical advancement, linking newer, faster, shinier supercomputers through thicker, faster links. ARPANET formally expired in 1989, a victim of its own success, but its users scarcely noticed as ARPANET's functions not only continued but improved. In 1971 only four nodes existed, today tens of thousands of nodes make up the network and 35 million of users make up the internet community. The internet is and institution that resists institutionalization. The internet community, belonging to everyone yet no-one, resembles our own community in many ways, and is susceptible to many of the same pressures. Business people want the internet put on sounder financial footing. Government people want the Internet more fully regulated. Academics want it dedicated exclusively to scholarly research. Military people want it spyproof and secure.